This Article Full Text Full Text (PDF) All Versions of this Article: 109/4/481    most recent 01.CIR.0000109695.39671.37v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Takamori, N. Articles by Matsumoto, T. Search for Related Content PubMed PubMed Citation Articles by Takamori, N. Articles by Matsumoto, T. Related Collections Restenosis Risk Factors Smooth muscle proliferation and differentiation Arterial thrombosis Thrombin Other anticoagulants Catheter-based coronary interventions: stents

(Circulation. 2004;109:481-486.)
© 2004 American Heart Association, Inc.

Clinical Investigation and Reports

High Plasma Heparin Cofactor II Activity Is Associated With Reduced Incidence of In-Stent Restenosis After Percutaneous Coronary Intervention

Nobuyuki Takamori, MD; Hiroyuki Azuma, MD; Midori Kato, MD; Shunji Hashizume, MD; Ken-ichi Aihara, MD; Masashi Akaike, MD; Katsuya Tamura, MD; Toshio Matsumoto, MD

From the Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, Tokushima (N.T., H.A., M.K., S.H., K.A., M.A., T.M.), and Department of Cardiology, Health Insurance Naruto Hospital, Naruto (K.T.), Japan.

Correspondence to Hiroyuki Azuma, MD, Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine, 3-18-15 Kuramoto-cho, Tokushima 770-8503, Japan. E-mail hiroyuki{at}clin.med.tokushima-u.ac.jp

Received February 12, 2003; de novo received September 16, 2003; revision received October 24, 2003; accepted October 30, 2003.

Background— Thrombin plays an important role in the development of atherosclerosis and restenosis after percutaneous coronary intervention. Because heparin cofactor II (HCII) inhibits thrombin action in the presence of dermatan sulfate, which is abundantly present in arterial wall, HCII may affect vascular remodeling by modulating thrombin action. We hypothesized that patients with high plasma HCII activity may show a reduced incidence of in-stent restenosis (ISR).

Methods and Results— Sequential coronary arteries (n=166) with NIR stent (Boston Scientific Corp) implantation in 134 patients were evaluated before, immediately after, and at 6 months after percutaneous coronary intervention. Patients were divided into the following groups: high HCII (110%, 45 lesions in 36 patients), normal HCII (80% and <110%, 81 lesions in 66 patients), and low HCII (<80%, 40 lesions in 32 patients). Percent diameter stenosis at follow-up in the high-HCII group (18.7%) was significantly lower (P=0.046) than that in the normal-HCII group (30.3%) or the low-HCII group (29.0%). The ISR rate in the high-HCII group (6.7%) was significantly lower than that in the low-HCII group (30.0%) (P=0.0039). Furthermore, multivariate analysis demonstrated that high plasma HCII activity is an independent factor in reducing the incidence of angiographic restenosis (odds ratio, 0.953/1% increase of HCII; 95% CI, 0.911 to 0.998).

Conclusions— The results demonstrate that HCII may have a hitherto unrecognized effect in inhibiting ISR. The effect of HCII may be mediated by inactivating thrombin in injured arteries, thereby inhibiting vascular smooth muscle cell migration and proliferation.

Key Words: cardiovascular diseases • angioplasty • atherosclerosis • thrombin • dermatan sulfate

This article has been cited by other articles:

				L. He, T. K. Giri, C. P. Vicente, and D. M. Tollefsen Vascular dermatan sulfate regulates the antithrombotic activity of heparin cofactor II Blood, April 15, 2008; 111(8): 4118 - 4125. [Abstract] [Full Text] [PDF]

				C. P. Vicente, L. He, and D. M. Tollefsen Accelerated atherogenesis and neointima formation in heparin cofactor II deficient mice Blood, December 15, 2007; 110(13): 4261 - 4267. [Abstract] [Full Text] [PDF]

				M. Gaudino, N. Luciani, F. Glieca, C. Cellini, C. Pragliola, C. Trani, F. Burzotta, G. Schiavoni, A. Anselmi, and G. Possati Patients with in-stent restenosis have an increased risk of mid-term venous graft failure. Ann. Thorac. Surg., September 1, 2006; 82(3): 802 - 804. [Abstract] [Full Text] [PDF]

				T. K. Giri and D. M. Tollefsen Placental dermatan sulfate: isolation, anticoagulant activity, and association with heparin cofactor II Blood, April 1, 2006; 107(7): 2753 - 2758. [Abstract] [Full Text] [PDF]

				T. K. Giri, C. W. Ahn, K. K. Wu, and D. M. Tollefsen Letter to the Editor: Heparin Cofactor II Levels Do Not Predict the Development of Coronary Heart Disease: The Atherosclerosis Risk in Communities (ARIC) Study Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2689 - 2690. [Full Text] [PDF]

				D. O'Keeffe, S. T. Olson, N. Gasiunas, J. Gallagher, T. P. Baglin, and J. A. Huntington The Heparin Binding Properties of Heparin Cofactor II Suggest an Antithrombin-like Activation Mechanism J. Biol. Chem., November 26, 2004; 279(48): 50267 - 50273. [Abstract] [Full Text] [PDF]

				J. Corral, J. Aznar, R. Gonzalez-Conejero, P. Villa, A. Minano, A. Vaya, R. W. Carrell, J. A. Huntington, and V. Vicente Homozygous Deficiency of Heparin Cofactor II: Relevance of P17 Glutamate Residue in Serpins, Relationship With Conformational Diseases, and Role in Thrombosis Circulation, September 7, 2004; 110(10): 1303 - 1307. [Abstract] [Full Text] [PDF]

				D. M. Tollefsen Does Heparin Cofactor II Modulate Atherosclerosis and Restenosis? Circulation, June 8, 2004; 109(22): 2682 - 2684. [Full Text] [PDF]